The present disclosure relates generally to stapled peptides, and pharmaceutical compositions thereof, which are useful for preventing and/or treating herpes simplex virus-1 (HSV-1) processive DNA synthesis, propagation, and/or infection in a subject. The present disclosure further provides methods for treating herpes simplex keratitis in a subject

The present disclosure relates generally to stapled peptides, and pharmaceutical compositions thereof, which are useful for preventing and/or treating herpes simplex virus-1 (HSV-1) processive DNA synthesis, propagation, and/or infection in a subject. The present disclosure further provides methods for treating herpes simplex keratitis in a subject

The present disclosure relates to methods for enhancing the efficiency of therapies involving immune effector cells such as T cells engineered to express antigen receptors such as T cell receptors (TCRs) or chimeric antigen receptors (CARs). It is demonstrated herein that such antigen receptor-engineered immune effector cells, even when provided to a subject in sub-therapeutic amounts, are extremely effective in the treatment of cancer diseases, even those cancer diseases that are known to be difficult to treat with antigen receptor-engineered immune effector cells, such as solid tumors or cancers, if additionally target antigen for the antigen receptor is provided to the subject. Immune effector cells may be engineered ex vivo or in vitro and subsequently the immune effector cells may be administered to a subject in need of treatment, or immune effector cells may be engineered in vivo in a subject in need of treatment.

Some embodiments pertain to nanoparticle-based compositions and their use in methods for the delivery of therapeutic ingredients to subjects. In some embodiments, the compositions are stable for prolonged periods of time and provide enhanced bioavailability.

Some embodiments pertain to nanoparticle-based compositions and their use in methods for the delivery of therapeutic ingredients to subjects. In some embodiments, the compositions are stable for prolonged periods of time and provide enhanced bioavailability.

The present disclosure is directed to a compound or compositions comprising the same for decreasing vascular permeability and the prevention or inhibition of metastasis in a cancer.

Provided herein are methods of preparing polyglutamated compounds, such as polyglutamated antifolates, and/or pharmaceutical compositions such as liposomal compositions comprising the same, Also provided herein are substantially pure polyglutamated compounds, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition such as liposomal composition comprising the same. The present disclosure further provides methods of using the polyglutamated compounds and compositions to treat diseases including hyperproliferative diseases such as cancer, disorders of the immune system such as rheumatoid arthritis, and infectious diseases such as HIV, malaria, and schistomiasis.

The disclosure features novel lipids and compositions involving the same. Lipid nanoparticles (e.g., empty LNPs or loaded LNPs) include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Lipid nanoparticles (e.g., empty LNPs or loaded LNPs) further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.

A serum exosome with high osteogenesis and high angiogenesis, a preparation method and an application thereof are provided, which belongs to the field of bone defect repair technologies. The serum exosome is derived from a serum in a fracture recovery period, and the fracture recovery period is in a range of a second week to a fifth week after fracture. It has been found that the exosomes extracted from the serum after fracture have stronger osteogenic and angiogenic properties than exosomes extracted from normal serum, which is helpful to solve problems that large segmental bone defects, extensive traumas and other diseases are difficult to repair, and provide a new therapy for all diseases that need to be repaired and cured through osteogenic and/or angiogenic properties.

A serum exosome with high osteogenesis and high angiogenesis, a preparation method and an application thereof are provided, which belongs to the field of bone defect repair technologies. The serum exosome is derived from a serum in a fracture recovery period, and the fracture recovery period is in a range of a second week to a fifth week after fracture. It has been found that the exosomes extracted from the serum after fracture have stronger osteogenic and angiogenic properties than exosomes extracted from normal serum, which is helpful to solve problems that large segmental bone defects, extensive traumas and other diseases are difficult to repair, and provide a new therapy for all diseases that need to be repaired and cured through osteogenic and/or angiogenic properties.